Table 2c.
Distribution of first trigger types and confirmed cases, by treatment arm, N=773 participants, by gender
| All | Placebo | Metformin | Intensive Lifestyle | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Males | Females | Males | Females | Males | Females | Males | Females | |||||||||
| N | Confirmed % (n) | n | Confirmed % (n) | n | Confirmed % (n) | n | Confirmed % (n) | n | Confirmed % (n) | n | Confirmed % (n) | n | Confirmed % (n) | n | Confirmed % (n) | |
| FPG (regardless of 2-hr) | 74 | 70.3 (52) | 124 | 58.9 (73) | 34 | 73.5 (25) | 60 | 63.3 (38) | 24 | 66.7 (16) | 37 | 59.5 (22) | 16 | 68.8 (11) | 27 | 48.2 (13) |
| 2-hr glucose (regardless of FPG) | 193 | 49.7 (96) | 478 | 46.0 (220) | 77 | 54.6 (42) | 186 | 51.1 (95) | 84 | 45.2 (38) | 184 | 45.1 (83) | 32 | 50.0 (16) | 108 | 38.9 (42) |
| Both* | 41 | 81.9 (34) | 56 | 75.0 (42) | 23 | 73.9 (17) | 34 | 70.6 (24) | 11 | 90.9 (10) | 12 | 91.7 (11) | 7 | 100.0 (7) | 10 | 70.0 (7) |
*
97 participants triggered on both FPG and 2-hr glucose